A new breast cancer clinical trial being performed nationwide may expedite the process of getting new drugs approved by the U.S. Food and Drug Administration, reports MSNBC.
The trial, given the name ISPY-2, is currently going on at 20 different medical centers and is backed by the Foundation for the National Institutes of Health. Scientists are researching a method known as neo-adjuvant chemotherapy – administering the chemo-hormone therapy prior to surgery, as opposed to the current approach of post-op therapy.
The study will show real-time results via an MRI scan so that doctors can determine whether or not the drugs are shrinking the tumor, which gives faster evidence to compare current methods to. With a speedier process, treatments can become more precise, as it will take far less time to see the effects of certain chemotherapy drugs.
“The truth of the matter is if you’re going to die of breast cancer, you’re not going to die of the tumor that’s in your breast,” Dr. Laura Esserman, the study’s lead researcher at the University of California, San Franciscio, told the news provider. “You’re going to die because the tumor has spread outside the breast and those cells can take up residence someplace else in your body. The only way you’re going to save that person is to make sure that you eradicate all of those cells wherever they may be and the sooner you start with the whole body treatment, the better off you’re going to be.”
The clinical trials are reportedly sponsored by Safeway’s food chain’s charitable foundation.

